Dr. M. Langeveld publications


Publications Dr. M. Langeveld

Main activities
Patient care, Research
Inherited metabolic disorders
Focus of research

My research focusses on inherited metabolic diseases in adults, with an emphasis on lysosomal storage disorders (LSDs). LSD research is embedded in SPHINX, a collaboration of the departments of Radiology, Internal Medicine and Paediatrics and the Laboratory of Genetic and Metabolic Diseases of the AMC. Within the LDSs, my main focus is Fabry disease, with the following ongoing research projects: 1. the characterisation of the antibody response to enzyme replacement therapy 2. cognitive symptoms in Fabry disease and their relation to white matter abnormalities. In addition we participate in an international trial studying the safety and efficacy of a new form of enzyme replacement therapy.

Other research activities are a an exploratory study into the role the microbiome in urea cycle disorders and supervision of a PhD project on skeletal complications in mucopolysaccharidosis and mucolipidosis. I’m an active member of the Internisten voor Erfelijke Stofwisselingsziekten (INVEST) group, currently coordinating the construction of the INVEST website, containing information on care of adults with inherited metabolic disorders in the Netherlands and Belgium (Vlaanderen).  



  • Bleeker JC, Kok IL, Ferdinandusse S, van der Pol WL, Cuppen I, Bosch AM, Langeveld M, Derks TGJ, Williams M, de Vries M, Mulder MF, Rubio Gozalbo E, van der Velden MGMdS, Rennings AJ, Schielen PJCI, Dekkers E, Houtkooper RH, Waterham HR, Pras-Raves ML, Wanders RJA, van Hasselt PM, Schoenmakers M, Wijburg FA, Visser G, Impact of NBS for VLCAD deficiency on genetic, enzymatic and clinical outcomes. J INHERIT METAB DIS 2019;ahead of print [PubMed]


  • Langeveld M, Editorial commentary: Newborn screening for Fabry disease: Too much too soon?. TRENDS CARDIOVAS MED 2018;28 (4):282-283 [PubMed]
  • Langeveld M, Elstein D, Szer J, Hollak CEM, Zimran A, Classifying the additional morbidities of Gaucher disease. BLOOD CELL MOL DIS 2018;68:209-210 [PubMed]
  • Langeveld M, Hollak CEM, Bone health in patients with inborn errors of metabolism. REV ENDOCR METAB DIS 2018;19 (1):81-92 [PubMed]
  • Oussoren E, van Eerd D, Murphy E, Lachmann R, van der Meijden JC, Hoefsloot LH, Verdijk R, Ruijter GJG, Maas M, Hollak CEM, Langendonk JG, van der Ploeg AT, Langeveld M, Mucolipidosis type III, a series of adult patients. J INHERIT METAB DIS 2018;41 (5):839-848 [PubMed]
  • Schuller Y, Arends M, Körver S, Langeveld M, Hollak CEM, Adaptive pathway development for Fabry disease: a clinical approach. DRUG DISCOV TODAY 2018;23 (6):1251-1257 [PubMed]
  • van der Veen SJ, van Kuilenburg ABP, Hollak CEM, Kaijen PHP, Voorberg J, Langeveld M, Antibodies against recombinant alpha-galactosidase A in Fabry disease: Subclass analysis and impact on response to treatment. MOL GENET METAB 2018;ahead of print [PubMed]
  • van Karnebeek CDM, Wortmann SB, Tarailo-Graovac M, Langeveld M, Ferreira CR, van de Kamp JM, Hollak CE, Wasserman WW, Waterham HR, Wevers RA, Haack TB, Wanders RJA, Boycott KM, The role of the clinician in the multi-omics era: are you ready?. J INHERIT METAB DIS 2018;41 (3):571-582 [PubMed]
  • van Vliet P, Berden AE, van Schie MKM, Bakker JA, Heringhaus C, de Coo IFM, Langeveld M, Schroijen MA, Arbous MS, Peripheral Neuropathy, Episodic Rhabdomyolysis, and Hypoparathyroidism in a Patient with Mitochondrial Trifunctional Protein Deficiency. JIMD REPORTS 2018;38:101-105 [PubMed]


  • Arends M, Wijburg FA, Wanner C, Vaz FM, van Kuilenburg ABP, Hughes DA, Biegstraaten M, Mehta A, Hollak CEM, Langeveld M, Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease. MOL GENET METAB 2017;121 (2):157-161 [PubMed]
  • Biewenga M, Matawlie RHS, Friesema ECH, Koole-Lesuis H, Langeveld M, Wilson JHP, Langendonk JG, Osteoporosis in patients with erythropoietic protoporphyria. BRIT J DERMATOL 2017;177 (6):1693-1698 [PubMed]
  • Burgard P, Ullrich K, Ballhausen D, Hennermann JB, Hollak CEM, Langeveld M, Karall D, Konstantopoulou V, Maier EM, Lang F, Lachmann R, Murphy E, Garbade S, Hoffmann GF, Kölker S, Lindner M, Zschocke J, Issues with European guidelines for phenylketonuria. LANCET DIABETES ENDO 2017;5 (9):681-683 [PubMed]
  • Langeveld M, Tan CY, Soeters MR, Virtue S, Watson LP, Murgatroyd PR, Ambler GK, Vidal-Puig S, Chatterjee KV, Vidal-Puig A, No metabolic effects of mustard allyl-isothiocyanate compared with placebo in men. AM J CLIN NUTR 2017;106 (5):1197-1205 [PubMed]
  • Oussoren E, Bessems JHJM, Pollet V, van der Meijden JC, van der Giessen LJ, Plug I, Devos AS, Ruijter GJG, van der Ploeg AT, Langeveld M, A long term follow-up study of the development of hip disease in Mucopolysaccharidosis type VI. MOL GENET METAB 2017;121 (3):241-251 [PubMed]


  • Hollak CEM, Biegstraaten M, Baumgartner MR, Belmatoug N, Bembi B, Bosch A, Brouwers M, Dekker H, Dobbelaere D, Engelen M, Groenendijk MC, Lachmann R, Langendonk JG, Langeveld M, Linthorst G, Morava E, Poll-The BT, Rahman S, Rubio-Gozalbo ME, Spiekerkoetter U, Treacy E, Wanders R, Zschocke J, Hagendijk R, Position statement on the role of healthcare professionals, patient organizations and industry in European Reference Networks. ORPHANET J RARE DIS 2016;11 (1):7 [PubMed]
  • Langeveld M, Tan CY, Soeters MR, Virtue S, Ambler GK, Watson LPE, Murgatroyd PR, Chatterjee VK, Vidal-Puig A, Mild cold effects on hunger, food intake, satiety and skin temperature in humans. ENDOCR CONNECT 2016;5 (2):65-73 [PubMed]


  • Langeveld M, DeVries JH, The long-term effect of energy restricted diets for treating obesity. OBESITY 2015;23 (8):1529-1538 [PubMed]


  • Langeveld M, de Vries JHH, Het magere resultaat van diëten. NED TIJDSCHR GENEESKD 2013;157 (29):A6017 [PubMed]


  • Langeveld M, van den Berg SAA, Bijl N, Bijland S, van Roomen CP, Houben-Weerts JH, Ottenhoff R, Houten SM, van Dijk KW, Romijn JA, Groen AK, Aerts JM, Voshol PJ, Treatment of genetically obese mice with the iminosugar N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin reduces body weight by decreasing food intake and increasing fat oxidation. METABOLISM 2012;61 (1):99-107 [PubMed]


  • Aerts JM, Boot RG, van Eijk M, Groener J, Bijl N, Lombardo E, Bietrix FM, Dekker N, Groen AK, Ottenhoff R, van Roomen C, Aten J, Serlie M, Langeveld M, Wennekes T, Overkleeft HS, Glycosphingolipids and insulin resistance. ADV EXP MED BIOL 2011;721:99-119 [PubMed]
  • Biegstraaten M, van Schaik IN, Aerts JMFG, Langeveld M, Mannens MMAM, Bour LJ, Sidransky E, Tayebi N, Fitzgibbon E, Hollak CEM, A monozygotic twin pair with highly discordant Gaucher phenotypes. BLOOD CELL MOL DIS 2011;46 (1):39-41 [PubMed]


  • Aerts JM, Boot RG, van Eijk M, Groener J, Bijl N, Lombardo E, Bietrix FM, Dekker N, Groen AK, Ottenhoff R, van Roomen C, Aten J, Serlie M, Langeveld M, Wennekes T, Overkleeft HS. Glycosphingolipids and insulin resistance in: Cowart A, editor. Sphingolipids and Metabolic Disease. S.l.: Landes Bioscience and Springer Science; 2010., p. 20-41


  • Bijl N, Sokolović M, Vrins C, Langeveld M, Moerland PD, Ottenhoff R, van Roomen CPAA, Claessen N, Boot RG, Aten J, Groen AK, Aerts JMFG, van Eijk M, Modulation of Glycosphingolipid Metabolism Significantly Improves Hepatic Insulin Sensitivity and Reverses Hepatic Steatosis in Mice. HEPATOLOGY 2009;50 (5):1431-1441 [PubMed]
  • de Fost M, Langeveld M, Franssen R, Hutten BA, Groener JEM, de Groot E, Mannens MM, Bikker H, Aerts JMFG, Kastelein JJP, Hollak CEM, Low HDL cholesterol levels in type I Gaucher disease do not lead to an increased risk of cardiovascular disease. ATHEROSCLEROSIS 2009;204 (1):267-272 [PubMed]
  • Langeveld M. Studies on the role of glycosphingolipids in metabolism. s.l.: s.n.; 2009. 204p. [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Aerts JMFG, Hollak CEM; copromotor(s): )
  • Langeveld M, Aerts JMFG, Glycosphingolipids and insulin resistance. PROG LIPID RES 2009;48 (3-4):196-205 [PubMed]


  • Ghauharali-van der Vlugt K, Langeveld M, Poppema A, Kuiper S, Hollak CEM, Aerts JM, Groener JEM, Prominent increase in plasma ganglioside GM3 is associated with clinical manifestations of type I Gaucher disease. CLIN CHIM ACTA 2008;389 (1-2):109-113 [PubMed]
  • Langeveld M, de Fost M, Aerts JMFG, Sauerwein HP, Hollak CEM, Overweight, insulin resistance and type II diabetes in type I Gaucher disease patients in relation to enzyme replacement therapy. BLOOD CELL MOL DIS 2008;40 (3):428-432 [PubMed]
  • Langeveld M, Ghauharali KJM, Sauerwein HP, Ackermans MT, Groener JEM, Hollak CEM, Aerts JM, Serlie MJ, Type I Gaucher disease, a glycosphingolipid storage disorder, is associated with insulin resistance. J CLIN ENDOCR METAB 2008;93 (3):845-851 [PubMed]


  • Langeveld M, Endert E, Wiersinga WM, Aerts JMFG, Hollak CEM, Hypermetabolism in Gaucher disease type I is not associated with altered thyroid hormone levels. J INHERIT METAB DIS 2007;30 (6):985 [PubMed]
  • Langeveld M, Scheij S, Dubbelhuis P, Hollak CEM, Sauerwein HP, Simons P, Aerts JMFG, Very low serum adiponectin levels in patients with type 1 Gaucher disease without overt hyperglycemia. METABOLISM 2007;56 (3):314-319 [PubMed]


  • Boot RG, Verhoek M, Langeveld M, Renkema GH, Hollak CEM, Weening JJ, Donker-Koopman WE, Groener JE, Aerts JMFG, CCL18: a urinary marker of Gaucher cell burden in Gaucher patients. J INHERIT METAB DIS 2006;29 (4):564-571 [PubMed]
  • Langeveld M, Gamadia LE, ten Berge IJM, T-lymphocyte subset distribution in human spleen. EUR J CLIN INVEST 2006;36 (4):250-256 [PubMed]


  • Aerts JMFG, van Breemen MJ, Bussink AP, Brinkman J, Hollak CEM, Langeveld M, Linthorst GE, Vedder AC, de Fost M, The blood-brain barrier and treatment of lysosomal storage disease. INT CONGRESS SERIES 2005;1277:19-31